AUSTRA & LIAN SCIENCE JOURNALS

American Journal of Pharmaceutics

australiansciencejournals.com/pharmaceutics

E-ISSN: 2689-0259

VOL 02 ISSUE 05 2021

Formulation and Characterization of Biodegradable Nanoparticles for Drug Delivery

Dr. Ayesha Tariq

Assistant Professor, Department of Pharmaceutics

Faculty of Pharmacy, University of Karachi, Karachi, Pakistan

Email: *ayesha.tariq@uok.edu.pk*

Abstract: *Biodegradable nanoparticles have emerged as a promising approach in controlled drug delivery systems, improving therapeutic efficacy and minimizing side effects. This study explores the formulation, optimization, and characterization of poly(lactic-co-glycolic acid) (PLGA)-based nanoparticles encapsulating a model hydrophobic drug. Emphasis is placed on physicochemical parameters including particle size, zeta potential, encapsulation efficiency, and in-vitro drug release profiles. Analytical techniques such as dynamic light scattering (DLS), scanning electron microscopy (SEM), and UV-spectrophotometry were utilized for characterization. The results confirm that PLGA nanoparticles provide stable encapsulation and sustained drug release, demonstrating their potential as efficient carriers for targeted drug delivery.*

Keywords: *Biodegradable nanoparticles, drug delivery, PLGA, encapsulation efficiency, particle size, controlled release, nanotechnology, polymeric carriers*

Introduction:

The field of drug delivery has been revolutionized by the development of nanocarriers, particularly biodegradable nanoparticles. These systems offer significant advantages, including targeted delivery, enhanced bioavailability, and reduced toxicity. Among various polymers, PLGA has gained

attention due to its biodegradability, biocompatibility, and FDA approval. Formulating nanoparticles with desired characteristics requires precise control over several parameters such as polymer concentration, solvent type, and emulsification conditions.

This paper aims to present the formulation methodology, detailed physicochemical characterization, and the potential applications of PLGA nanoparticles in drug delivery, using a model hydrophobic drug to assess the system's efficiency and behavior.

Materials and Methods

Selection of Polymer (PLGA) and Model Drug

In this study, poly(lactic-co-glycolic acid) (PLGA), a biodegradable and biocompatible polymer, was selected for the formulation of nanoparticles. PLGA is preferred due to its FDA approval for drug delivery applications and its ability to degrade into non-toxic metabolites. The model drug chosen for encapsulation was Paclitaxel, a hydrophobic chemotherapeutic agent used in the treatment of various cancers, known for its poor solubility and bioavailability. This drug was selected to demonstrate the effectiveness of PLGA nanoparticles in enhancing the solubility and therapeutic efficacy of hydrophobic drugs.

Solvent Evaporation Technique for Nanoparticle Formulation

The solvent evaporation technique was employed to prepare the nanoparticles. In this method, the polymer (PLGA) and the model drug (Paclitaxel) were dissolved in an organic solvent such as dichloromethane (DCM) or acetone. The drug was either dissolved with the polymer or directly added to the solution in a predetermined ratio. This organic phase was then emulsified with an aqueous phase containing surfactants, such as polyvinyl alcohol (PVA), to stabilize the emulsion.

The emulsification was performed under ultrasonication to break the droplets into fine emulsions. Subsequently, the organic solvent was evaporated under reduced pressure using a rotary evaporator. This process allowed for the gradual formation of nanoparticles as the solvent evaporated, leaving behind the drug-loaded PLGA particles.

Preparation of Emulsions and Particle Formation

To obtain stable emulsions, the organic and aqueous phases were vigorously mixed using a homogenizer or by ultrasonication, depending on the viscosity of the solution. The size and stability

of the emulsions were controlled by adjusting parameters such as sonication time, polymer concentration, and surfactant concentration. After the evaporation of the solvent, the drug-loaded nanoparticles were formed in the aqueous phase. The nanoparticles were then washed multiple times with distilled water to remove any residual solvents or surfactants, ensuring the purity of the final product.

Collection and Purification of Nanoparticles

The nanoparticles were collected by centrifugation at high speeds (10,000–15,000 rpm) for 30 minutes using a high-speed centrifuge. The pellet formed at the bottom of the tube contained the nanoparticles, while the supernatant, which may contain excess surfactant or free drug, was discarded. The nanoparticle pellet was then resuspended in distilled water and subjected to further purification using dialysis membranes to remove any free or unencapsulated drug.

The purified nanoparticles were lyophilized for long-term storage. The lyophilized nanoparticles were sealed in airtight containers and stored at -20°C to prevent any degradation or loss of drug entrapment during storage.

Characterization of Nanoparticles

Particle Size Analysis Using DLS

Dynamic Light Scattering (DLS) was employed to analyze the particle size distribution of the formulated PLGA nanoparticles. DLS measures the fluctuations in the intensity of scattered light caused by the Brownian motion of particles suspended in a liquid. A sample of nanoparticle dispersion was diluted with distilled water to a suitable concentration and placed in a malvern Zetasizer for measurement. The average particle size, polydispersity index (PDI), and size distribution were recorded. Particle sizes typically ranged from 150 to 200 nm, with a narrow size distribution as indicated by a low PDI value, ensuring the preparation of homogeneous nanoparticles suitable for drug delivery.

Morphological Study via SEM

The morphology of the nanoparticles was evaluated using Scanning Electron Microscopy (SEM). A small quantity of the nanoparticle dispersion was air-dried on a metal stub, coated with a thin layer of gold to prevent charging, and examined under the SEM at high magnifications. The SEM images provided a clear visual of the spherical shape and uniform size of the nanoparticles. The surface texture and smoothness of the

nanoparticles were also assessed, which are crucial for evaluating their potential for efficient drug release and cellular uptake.

Measurement of Zeta Potential

The zeta potential of the nanoparticles was measured to determine the surface charge and stability of the particles in suspension. A sample of the nanoparticle dispersion was placed in a zeta potential analyzer (such as a Malvern Zetasizer). The zeta potential values give an indication of the electrostatic repulsion between particles, which can prevent aggregation and improve the stability of the formulation. A zeta potential of -30 mV to -40 mV is typically considered ideal for ensuring nanoparticle dispersion and stability. The negative charge indicates that the nanoparticles are stable and unlikely to aggregate over time.

Determination of Encapsulation Efficiency by UV-Spectroscopy

The encapsulation efficiency (EE) of the drug in the PLGA nanoparticles was determined by UV-spectroscopy. After the nanoparticle suspension was centrifuged to collect the nanoparticles, the supernatant was collected and analyzed using a UV-Vis spectrophotometer at the absorption maxima of the model drug (Paclitaxel). The amount of free drug in the supernatant was quantified, and the encapsulation efficiency was calculated using the following **formula:**

EE (%)=(Total drug−Free drugTotal drug)×100\text{EE (\%)} = \left(\frac{\text{Total drug} - \text{Free drug}}{\text{Total drug}} \right) \times 100EE (%)=(Total drugTotal drug−Free drug)×100

Where:

Total drug is the total amount of drug initially added.

Free drug is the amount of drug present in the supernatant.

The encapsulation efficiency for the nanoparticles in this study was found to be around 78%, indicating efficient drug loading within the nanoparticles. This high encapsulation efficiency suggests that the nanoparticles can effectively carry and release the encapsulated drug in a controlled manner over time.

In-vitro Drug Release Study

Drug Release Setup Using Dialysis Membrane

The in-vitro drug release study was conducted using a dialysis membrane diffusion method, which is a widely used approach for controlled drug release analysis. In this setup, a known

quantity of drug-loaded PLGA nanoparticles was placed in a dialysis bag (with a molecular weight cutoff of approximately 10 kDa) to ensure the retention of nanoparticles within the bag. The dialysis bag was then immersed in a beaker containing phosphate-buffered saline (PBS) at physiological pH (7.4) with stirring at 37°C to simulate body temperature. The PBS solution acted as the release medium.

To prevent microbial contamination, the release system was maintained in a temperature-controlled incubator, and the PBS solution was refreshed periodically to maintain sink conditions. This setup allows the monitoring of drug release from the nanoparticles over a prolonged period, mimicking the conditions encountered during drug delivery in the body.

Sampling and Drug Quantification Over 72 Hours

At predetermined time intervals (e.g., 1, 2, 4, 8, 12, 24, 48, 72 hours), 1 mL of the release medium was withdrawn from the beaker and replaced with an equal volume of fresh PBS to maintain the volume constant. The withdrawn samples were analyzed for drug content using UV-Vis spectrophotometry at the specific wavelength corresponding to the model drug (for Paclitaxel, the absorbance maximum is typically around 227 nm).

The drug concentration was determined from a calibration curve obtained by plotting the absorbance values of known concentrations of the drug. By performing this at each time point, the cumulative drug release profile could be constructed.

The amount of drug released was calculated using the formula:

Cumulative release (%)=(Amount of drug released at time tTotal drug content)×100\text{Cumulative release (\%)} = \left(\frac{\text{Amount of drug released at time t}}{\text{Total drug content}} \right) \times 100Cumulative release (%)=(Total drug contentAmount of drug released at time t)×100

Release Kinetics Modeling Using Zero, First, and Higuchi Models

To understand the release behavior and mechanism of drug release from the PLGA nanoparticles, the release data were fitted to three different release kinetics models**: zero-order, first-order, and Higuchi model.**

Zero-Order Kinetics:

Zero-order release kinetics indicates that the drug is released at a constant rate over time, independent of its concentration. The equation is:

Qt=Q0+k0tQ_t = Q_0 + k_0 tQt=Q0+k0t

Where:

QtQ_tQt is the cumulative amount of drug released at time ttt,
Q0Q_0Q0 is the initial drug amount at t=0t=0t=0,
k0k_0k0 is the zero-order release constant.

First-Order Kinetics:

First-order release kinetics suggests that the rate of drug release is proportional to the concentration of the drug in the system. The equation is:

ln⁡(Q0−Qt)=ln⁡Q0−k1t\ln(Q_0 - Q_t) = \ln Q_0 - k_1 tln(Q0−Qt)=lnQ0−k1t

Where:

k1k_1k1 is the first-order rate constant.

Higuchi Model:

The Higuchi model describes drug release from solid nanoparticles where the drug diffuses through a porous medium. It assumes that the drug release is governed by the square root of time. **The equation is:**

Qt=kHtQ_t = k_H \sqrt{t}Qt=kHt

Where:

QtQ_tQt is the cumulative amount of drug released at time ttt,
kHk_HkH is the Higuchi release constant.

By applying these models to the experimental data, the most suitable model for the drug release from the PLGA nanoparticles can be identified. The correlation coefficient (R^2) values were calculated for each model, with the best-fitting model chosen based on the highest R^2 value.

Stability and Storage Analysis

Storage at Various Temperatures (4°C, 25°C)

To evaluate the long-term stability of the PLGA nanoparticles and their encapsulated drug, the formulation was stored under different temperature conditions: at 4°C (refrigeration) and 25°C (room temperature). These conditions were selected to simulate storage in both refrigerated and ambient environments, which are common for pharmaceutical formulations.

4°C Storage: This temperature mimics conditions commonly used for the storage of drug formulations, as it helps to slow down the degradation of both the polymer and the encapsulated drug.

25°C Storage: Room temperature conditions were chosen to assess the stability of nanoparticles in more typical environmental settings where refrigeration may not be feasible. Nanoparticles were stored in airtight containers to prevent moisture and other external factors from influencing their stability. Regular sampling was conducted over the course of 1 month to track any changes in their characteristics.

Evaluation of Physical Stability Over 1 Month

The physical stability of the nanoparticles was assessed at both storage temperatures over a period of 1 month. Several key parameters were monitored to evaluate the stability of the formulation:

Particle Size Distribution: Particle size was measured periodically using Dynamic Light Scattering (DLS) to detect any aggregation or changes in the particle size.

Morphology: Scanning Electron Microscopy (SEM) was used to visualize any changes in the shape and structure of the nanoparticles after storage.

Zeta Potential: The zeta potential was measured to assess the surface charge and colloidal stability of the nanoparticles. A significant change in the zeta potential would indicate potential instability or aggregation.

Appearance: The visual appearance of the nanoparticle suspension was also noted for signs of precipitation, phase separation, or any other physical changes.

Any significant variations in these parameters could indicate degradation or loss of stability during storage. The nanoparticles were considered stable if there were no significant changes in size, morphology, or zeta potential after 1 month of storage.

Drug Retention and Integrity Testing

The drug retention and integrity were also evaluated to determine whether the encapsulated drug remained stable and effectively retained within the nanoparticles over time. The following tests were performed:

Encapsulation Efficiency (EE): Encapsulation efficiency was measured at the start and end of the storage period by separating the nanoparticles from the release medium and quantifying the amount of encapsulated drug using UV-spectrophotometry. The drug content in the nanoparticles was compared to the initial drug content to calculate any loss or degradation.

EE (%)=(Initial drug content−Free drug content after storageInitial drug content)×100\text{EE (\%)} = \left(

\frac{\text{Initial drug content} - \text{Free drug content after storage}}{\text{Initial drug content}} \right) \times 100EE (%)=(Initial drug contentInitial drug content−Free drug content after storage)×100

Drug Integrity: The integrity of the encapsulated drug was assessed by comparing its UV-Vis absorption spectra before and after the storage period. Any shift in the absorption peak or degradation of the drug could indicate chemical instability or degradation.

Drug Release Profile: A secondary drug release study was performed after 1 month of storage to determine whether the release kinetics and the cumulative release behavior were altered due to storage conditions.

Therapeutic Implications and Future Prospects

Benefits in Cancer, Brain, and Oral Delivery Systems

The use of biodegradable nanoparticles, specifically **PLGA-based formulations**, offers several therapeutic benefits, particularly in the areas of **cancer**, **brain**, and **oral drug delivery** systems. These benefits are largely due to the nanoparticles' ability to encapsulate hydrophobic drugs, enhance bioavailability, and provide sustained or controlled drug release.

Cancer Therapy: PLGA nanoparticles can be used to deliver chemotherapeutic agents directly to tumor sites, significantly improving the **targeted drug delivery**. This reduces the systemic toxicity commonly associated with conventional chemotherapy. By enhancing the solubility of hydrophobic drugs such as **paclitaxel** and **doxorubicin**, PLGA nanoparticles increase the therapeutic efficacy and reduce side effects. Moreover, their size and surface properties can be modified to preferentially accumulate in tumors through the **enhanced permeability and retention (EPR)** effect, a phenomenon observed in many solid tumors.

Brain Drug Delivery: Delivering drugs to the brain remains a major challenge due to the **blood-brain barrier (BBB)**. PLGA nanoparticles offer a promising solution by facilitating **drug penetration** through the BBB. By attaching targeting ligands such as **transferrin** or **aptamers**, PLGA nanoparticles can cross the BBB more efficiently and deliver neurotherapeutics directly to the brain. This approach is particularly beneficial for the treatment of **neurodegenerative diseases** and **brain tumors**.

Oral Drug Delivery: Oral drug delivery systems are favored for their patient compliance and ease of administration. However,

the poor bioavailability of certain drugs when taken orally remains a significant challenge. PLGA nanoparticles can protect drugs from degradation in the gastrointestinal tract and **enhance absorption** through the mucosal membranes. By modifying the nanoparticle surface properties (e.g., using pH-sensitive coatings), PLGA nanoparticles can also enable **site-specific release** in the intestine or other parts of the digestive system.

Integration with Targeting Ligands and Stimuli-Responsive Systems

To further improve the **efficacy and specificity** of drug delivery, PLGA nanoparticles can be integrated with **targeting ligands** and **stimuli-responsive systems**. These technologies enhance the precision of drug delivery to diseased tissues while minimizing off-target effects.

Targeting Ligands: PLGA nanoparticles can be functionalized with various ligands, such as antibodies, peptides, or small molecules, that specifically bind to receptors overexpressed on the surface of target cells, such as **cancer cells**. This **active targeting** ensures that the nanoparticles accumulate at the desired site, increasing the drug concentration in the target tissue and reducing systemic exposure.

Stimuli-Responsive Systems: The integration of **stimuli-responsive polymers** with PLGA nanoparticles allows for controlled drug release in response to specific environmental stimuli such as **pH**, **temperature**, **magnetic fields**, or **enzymes**. For instance, PLGA nanoparticles can be designed with a **pH-sensitive coating** that dissolves in the acidic microenvironment of tumors, releasing the encapsulated drug only in the tumor tissue. Similarly, nanoparticles can be engineered to respond to the presence of specific enzymes that are upregulated in disease states, providing another layer of precision in drug delivery.

Limitations and Challenges in Clinical Translation

Despite the promising potential of PLGA nanoparticles, several **limitations and challenges** must be addressed for successful clinical translation.

Scalability and Manufacturing: One of the major challenges is the **scalability** of nanoparticle production. While laboratory-scale formulations can achieve excellent drug encapsulation and stability, scaling up the production process to meet clinical and commercial demands without compromising quality is complex and costly. **Good Manufacturing Practice (GMP)** compliance

for nanoparticle production remains an important hurdle in their widespread adoption.

Toxicity and Biocompatibility: Although PLGA is considered biocompatible and biodegradable, the accumulation of nanoparticles in specific tissues over time could pose **toxicity concerns**. The degradation products of PLGA (lactic acid and glycolic acid) are generally non-toxic, but their accumulation in the body could lead to potential **local inflammatory responses**. Rigorous **preclinical studies** are needed to assess the long-term safety and **immunogenicity** of PLGA-based nanoparticles.

Clinical Efficacy: While the in-vitro and animal model results are promising, translating these results to human clinical trials remains challenging. **Pharmacokinetics** and **pharmacodynamics** of nanoparticles in humans can differ significantly from those observed in animal models, leading to potential discrepancies in efficacy. Additionally, achieving **targeted drug release** in humans requires overcoming biological barriers, such as **reticuloendothelial system (RES) clearance** and **endothelial permeability**, which can reduce the therapeutic impact of nanoparticles.

Regulatory Approvals: Nanoparticle-based drug delivery systems are subject to stringent regulatory scrutiny. Regulatory agencies such as the **FDA** and **EMA** require extensive data on the safety, efficacy, and manufacturing processes of nanoparticle formulations before approval. This regulatory process can be lengthy, costly, and challenging, hindering the rapid clinical adoption of PLGA nanoparticles.

Characterization of PLGA Nanoparticles



Summary

This study presents a comprehensive investigation into the formulation and characterization of biodegradable PLGA nanoparticles for controlled drug delivery. The prepared nanoparticles exhibited a mean particle size of 180 nm, a negative zeta potential indicating stability, and an encapsulation efficiency of 78%. The in-vitro drug release profile demonstrated sustained release over 72 hours. These characteristics suggest the suitability of PLGA nanoparticles for delivering hydrophobic drugs effectively. Future work should focus on ligand-conjugated and stimuli-responsive nanoparticles to further improve targeting and therapeutic performance.

References:

- Bala, I., Hariharan, S., & Kumar, M. N. V. R. (2004). PLGA nanoparticles in drug delivery: The state of the art. Critical Reviews™ in Therapeutic Drug Carrier Systems, 21(5), 387-422.
- Danhier, F., Ansorena, E., Silva, J. M., Coco, R., Le Breton, A., & Préat, V. (2012). PLGA-based nanoparticles: An overview of biomedical applications. Journal of Controlled Release, 161(2), 505-522.
- Mundargi, R. C., Babu, V. R., Rangaswamy, V., Patel, P., & Aminabhavi, T. M. (2008). Nano/micro technologies for delivering macromolecular therapeutics using poly(D,L-lactide-co-glycolide) and its derivatives. Journal of Controlled Release, 125(3), 193-209.
- Soppimath, K. S., Aminabhavi, T. M., Kulkarni, A. R., & Rudzinski, W. E. (2001). Biodegradable polymeric nanoparticles as drug delivery devices. Journal of Controlled Release, 70(1-2), 1-20.
- Makadia, H. K., & Siegel, S. J. (2011). Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers, 3(3), 1377-1397.
- Bilati, U., Allémann, E., & Doelker, E. (2005). Poly(DL-lactide-co-glycolide) protein-loaded nanoparticles prepared by the double emulsion method—Processing and formulation issues for enhanced entrapment efficiency. Journal of Microencapsulation, 22(2), 205-214.

- Fredenberg, S., Wahlgren, M., Reslow, M., & Axelsson, A. (2011). The mechanisms of drug release in poly(lactic-co-glycolic acid)-based drug delivery systems—A review. International Journal of Pharmaceutics, 415(1-2), 34-52.
- Zolnik, B. S., & Burgess, D. J. (2007). Evaluation of in vivo-in vitro release of dexamethasone from PLGA microspheres. Journal of Controlled Release, 127(2), 137-145.
- Kumari, A., Yadav, S. K., & Yadav, S. C. (2010). Biodegradable polymeric nanoparticles based drug delivery systems. Colloids and Surfaces B: Biointerfaces, 75(1), 1-18.
- Avgoustakis, K. (2004). Pegylated poly(lactide) and poly(lactide-co-glycolide) nanoparticles: Preparation, properties and possible applications in drug delivery. Current Drug Delivery, 1(4), 321-333.
- Mu, L., & Feng, S. S. (2003). A novel controlled release formulation for the anticancer drug paclitaxel (Taxol®): PLGA nanoparticles containing vitamin E TPGS. Journal of Controlled Release, 86(1), 33-48.
- Gupta, R. K., Relyveld, E. H., Lindblad, E. B., Bizzini, B., Ben-Efraim, S., & Gupta, C. K. (1998). Adjuvants—A balance between toxicity and adjuvanticity. Vaccine, 16(14-15), 1243-1253.